| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T229 |
0-78 |
Sentence |
denotes |
What Are Common Gastrointestinal/Liver Adverse Effects of COVID-19 Treatments? |
| T230 |
79-176 |
Sentence |
denotes |
`There are currently no US Food and Drug Administration–approved routine treatments for COVID-19. |
| T231 |
177-399 |
Sentence |
denotes |
The FDA has issued an emergency use authorization for 3 therapies: choloroquine or hydroxychloroquine, remdesivir, and convalescent plasma.82 In China and Japan, favipiravir has been approved for the treatment of COVID-19. |
| T232 |
400-733 |
Sentence |
denotes |
Numerous medications are under investigation; the World Health Organization is spearheading a multinational, multicenter trial for the 5 treatments highlighted below.83 We aim to provide a summary of the Gl and liver adverse effects of the most commonly utilized medications for COVID-19 at this time, irrespective of their efficacy. |
| T233 |
734-874 |
Sentence |
denotes |
Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources). |
